Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of PF-06649751 in Subjects with Parkinson's Disease
2017-000128-81Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Pfizer. Primary endpoint: Adverse events. Started Jul 2017; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-000128-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000128-81.